Taro Pharmaceuticals
Nigeria 2 duplicate records merged Updated 9 July 2026
Taro Pharmaceuticals is a finished-dose manufacturer based in Nigeria. It appears in 1,224 regulatory filings across 17 regulators, without an active US DMF or CEP on file. Its filings concentrate with Health Canada, NMRC (NA) and MPA (SE). Its GMP standing is certified by NAFDAC (NG). Its most recent recorded inspection, by US FDA, closed on 8 December 2022 as NAI.
2
registered plants
1 with an FDA FEI number
1,224
filings
across 17 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
7 of 7 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 8 December 2022 NAI US FDA
- 11 July 2019 VAI US FDA
- 5 February 2017 VAI US FDA
- 21 May 2015 VAI US FDA
- 6 December 2012 NAI US FDA
- 28 May 2010 VAI US FDA
- 10 September 2009 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Israel, Israel | 3002808385 |
| Paonta Sahib, Nigeria | Not on file |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| Health Canada | 666 | None |
| NMRC (NA) | 159 | None |
| MPA (SE) | 110 | None |
| US FDA | 77 | None |
| ARCSA (EC) | 60 | None |
| DKMA (DK) | 41 | None |
| NAFDAC (NG) | None | 3 |
Comparing suppliers?
Choose your molecules and target markets. Taro Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 8 December 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates